Cargando…

Clinical Application of the HCM-AF Risk Score in the Prediction of Clinical Outcomes of Polish Patients with Hypertrophic Cardiomyopathy

The recently introduced HCM-AF Risk Calculator allows the prognosis of atrial fibrillation (AF) occurrence in hypertrophic cardiomyopathy (HCM) patients. The aim of this study was to assess the clinical application of the HCM-AF Risk Score in the prediction of the clinical outcomes of Polish patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Stec, Maria, Suleja, Agata, Gondko, Daniel, Kuczmik, Wiktoria, Roman, Jakub, Dziadosz, Dominika, Szydło, Krzysztof, Mizia-Stec, Katarzyna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10342482/
https://www.ncbi.nlm.nih.gov/pubmed/37445519
http://dx.doi.org/10.3390/jcm12134484
_version_ 1785072509570252800
author Stec, Maria
Suleja, Agata
Gondko, Daniel
Kuczmik, Wiktoria
Roman, Jakub
Dziadosz, Dominika
Szydło, Krzysztof
Mizia-Stec, Katarzyna
author_facet Stec, Maria
Suleja, Agata
Gondko, Daniel
Kuczmik, Wiktoria
Roman, Jakub
Dziadosz, Dominika
Szydło, Krzysztof
Mizia-Stec, Katarzyna
author_sort Stec, Maria
collection PubMed
description The recently introduced HCM-AF Risk Calculator allows the prognosis of atrial fibrillation (AF) occurrence in hypertrophic cardiomyopathy (HCM) patients. The aim of this study was to assess the clinical application of the HCM-AF Risk Score in the prediction of the clinical outcomes of Polish patients. The study included 92 patients (50.0% female, median age 55 years), with a baseline sinus rhythm diagnosed between 2013 and 2018. The analysis involved the incidence of clinical characteristics and outcomes, total mortality, rehospitalisation, and the course of heart failure (HF). According to the HCM-AF Risk Score, the HCM population was stratified into three subgroups, with a low (13/14.2%), intermediate (30/32.6%), and high risk of AF (49/53.2%). Subgroups differed significantly: the high-risk subgroup was older, had a higher body mass index (BMI), and more advanced signs of left ventricular (LV) hypertrophy and left atrium (LA) dilatation. The registered AF incidence was 31.5% and 43.5% in the 2- and 5-year follow-ups, and it was significantly higher than in the HCM-AF Risk Score population, which had 4.6% in the 2-year follow-up, and 10.7% in the 5-year follow-up. In the whole population, the AF incidence in both the 2- and 5-year follow-ups revealed a strong correlation with the HCM-AF Risk Score (r = 0.442, p < 0.001; r = 0.346, p < 0.001, respectively). The clinical outcomes differed among the subgroups: the total mortality was 15.4% vs. 20.0% vs. 42.9% (p < 0.05); rehospitalisation was 23.1% vs. 53.3% vs. 71.4% (p < 0.05). The highest HF progression was in the high-risk subgroup (36.7%). Regardless of the high results of the HCM-Risk Score in Polish patients, the score underestimates the real-life high level of AF incidence. The HCM-AF Risk Score seems to be useful in the prediction of the general clinical outcomes in HCM patients.
format Online
Article
Text
id pubmed-10342482
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-103424822023-07-14 Clinical Application of the HCM-AF Risk Score in the Prediction of Clinical Outcomes of Polish Patients with Hypertrophic Cardiomyopathy Stec, Maria Suleja, Agata Gondko, Daniel Kuczmik, Wiktoria Roman, Jakub Dziadosz, Dominika Szydło, Krzysztof Mizia-Stec, Katarzyna J Clin Med Article The recently introduced HCM-AF Risk Calculator allows the prognosis of atrial fibrillation (AF) occurrence in hypertrophic cardiomyopathy (HCM) patients. The aim of this study was to assess the clinical application of the HCM-AF Risk Score in the prediction of the clinical outcomes of Polish patients. The study included 92 patients (50.0% female, median age 55 years), with a baseline sinus rhythm diagnosed between 2013 and 2018. The analysis involved the incidence of clinical characteristics and outcomes, total mortality, rehospitalisation, and the course of heart failure (HF). According to the HCM-AF Risk Score, the HCM population was stratified into three subgroups, with a low (13/14.2%), intermediate (30/32.6%), and high risk of AF (49/53.2%). Subgroups differed significantly: the high-risk subgroup was older, had a higher body mass index (BMI), and more advanced signs of left ventricular (LV) hypertrophy and left atrium (LA) dilatation. The registered AF incidence was 31.5% and 43.5% in the 2- and 5-year follow-ups, and it was significantly higher than in the HCM-AF Risk Score population, which had 4.6% in the 2-year follow-up, and 10.7% in the 5-year follow-up. In the whole population, the AF incidence in both the 2- and 5-year follow-ups revealed a strong correlation with the HCM-AF Risk Score (r = 0.442, p < 0.001; r = 0.346, p < 0.001, respectively). The clinical outcomes differed among the subgroups: the total mortality was 15.4% vs. 20.0% vs. 42.9% (p < 0.05); rehospitalisation was 23.1% vs. 53.3% vs. 71.4% (p < 0.05). The highest HF progression was in the high-risk subgroup (36.7%). Regardless of the high results of the HCM-Risk Score in Polish patients, the score underestimates the real-life high level of AF incidence. The HCM-AF Risk Score seems to be useful in the prediction of the general clinical outcomes in HCM patients. MDPI 2023-07-04 /pmc/articles/PMC10342482/ /pubmed/37445519 http://dx.doi.org/10.3390/jcm12134484 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Stec, Maria
Suleja, Agata
Gondko, Daniel
Kuczmik, Wiktoria
Roman, Jakub
Dziadosz, Dominika
Szydło, Krzysztof
Mizia-Stec, Katarzyna
Clinical Application of the HCM-AF Risk Score in the Prediction of Clinical Outcomes of Polish Patients with Hypertrophic Cardiomyopathy
title Clinical Application of the HCM-AF Risk Score in the Prediction of Clinical Outcomes of Polish Patients with Hypertrophic Cardiomyopathy
title_full Clinical Application of the HCM-AF Risk Score in the Prediction of Clinical Outcomes of Polish Patients with Hypertrophic Cardiomyopathy
title_fullStr Clinical Application of the HCM-AF Risk Score in the Prediction of Clinical Outcomes of Polish Patients with Hypertrophic Cardiomyopathy
title_full_unstemmed Clinical Application of the HCM-AF Risk Score in the Prediction of Clinical Outcomes of Polish Patients with Hypertrophic Cardiomyopathy
title_short Clinical Application of the HCM-AF Risk Score in the Prediction of Clinical Outcomes of Polish Patients with Hypertrophic Cardiomyopathy
title_sort clinical application of the hcm-af risk score in the prediction of clinical outcomes of polish patients with hypertrophic cardiomyopathy
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10342482/
https://www.ncbi.nlm.nih.gov/pubmed/37445519
http://dx.doi.org/10.3390/jcm12134484
work_keys_str_mv AT stecmaria clinicalapplicationofthehcmafriskscoreinthepredictionofclinicaloutcomesofpolishpatientswithhypertrophiccardiomyopathy
AT sulejaagata clinicalapplicationofthehcmafriskscoreinthepredictionofclinicaloutcomesofpolishpatientswithhypertrophiccardiomyopathy
AT gondkodaniel clinicalapplicationofthehcmafriskscoreinthepredictionofclinicaloutcomesofpolishpatientswithhypertrophiccardiomyopathy
AT kuczmikwiktoria clinicalapplicationofthehcmafriskscoreinthepredictionofclinicaloutcomesofpolishpatientswithhypertrophiccardiomyopathy
AT romanjakub clinicalapplicationofthehcmafriskscoreinthepredictionofclinicaloutcomesofpolishpatientswithhypertrophiccardiomyopathy
AT dziadoszdominika clinicalapplicationofthehcmafriskscoreinthepredictionofclinicaloutcomesofpolishpatientswithhypertrophiccardiomyopathy
AT szydłokrzysztof clinicalapplicationofthehcmafriskscoreinthepredictionofclinicaloutcomesofpolishpatientswithhypertrophiccardiomyopathy
AT miziasteckatarzyna clinicalapplicationofthehcmafriskscoreinthepredictionofclinicaloutcomesofpolishpatientswithhypertrophiccardiomyopathy